الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 113 |  |  |
| | | from | 113 | | |
Abstract
Alopecia areata (AA) is a common, nonscarring, autoimmune disease that can affect any hair-bearing area. It is a lymphocyte cell-mediated inflammatory type of hair loss, but its pathogenesis is not fully understood. The disease can present as a single, well demarcated patch of hair loss, multiple patches, or extensive hair loss in a form of total loss of scalp hair (alopecia totalis) or loss of entire scalp and body hair (alopecia universalis).
A number of treatments can induce hair regrowth in alopecia areata but do not change the course of the disease. Ongoing research and new insights into mechanisms have led to proposals of innovative therapies. New directions include Janus kinase inhibitors (JAK), biologics targeting immune response as well as lasers and autologous platelet-rich plasma therapy.
It is generally agreed that intralesional corticosteroid are the treatment of choice for patchy hair loss in AA. Triamcinolone acetonide (TA) is the most commonly used intralesional corticosteroids; o.1 ml of the solution is injected into multiple sites, at 1 cm apart, into the deep dermis. This process is repeated every 4–6 weeks. A 5–10 mg/ml dosage is used as the initial concentration for the scalp, and a dosage of 2.5 mg/ml is used for areas on the face with a maximum dose of 20 mg for each visit.
In the present study, the aim was to evaluate the clinical efficacy and safety of low concentration of intralesional corticosteroids in treatment of different types of alopecia areata (patchy alopecia areata (scalp involvement <50%), extensive alopecia areata (scalp involvement >50%) and alopecia totalis). Twenty eight patients with different types of AA were randomly selected from Dermatology and Venereology Outpatient Clinics of Zagazig University Hospitals. They included 12 males (42.9%) and 16 females (57.1%), their ages ranged from 4-38 years with a mean of 21.57±12.4 years.